Sigbjørn Berentsen. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » AdolescentAdultAged, 80 and overAnemia, Hemolytic, Autoimmune/complicationsAnemia, Hemolytic, Autoimmune/drug therapyAnemia, Hemolytic, Autoimmune/mortalityAntibodies, Monoclonal/administration & dosageAntibodies, Monoclonal/adverse effectsAntibodies, Monoclonal, Murine-DerivedChildChild, PreschoolDisease-Free SurvivalFemaleHumansImmunologic Factors/administration & dosageImmunologic Factors/adverse effectsInfantInfections/chemically inducedInfections/mortalityMaleMiddle AgedNeutropenia/complicationsNeutropenia/drug therapyNeutropenia/mortalityPancytopenia/complicationsPancytopenia/drug therapyPancytopenia/mortalityPrednisolone/administration & dosagePrednisolone/adverse effectsPurpura, Thrombocytopenic, Idiopathic/complicationsPurpura, Thrombocytopenic, Idiopathic/drug therapyPurpura, Thrombocytopenic, Idiopathic/mortalityRed-Cell Aplasia, Pure/drug therapyRemission InductionRituximabSurvival RateSyndrome
Substances: See more » Antibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedImmunologic FactorsRituximabPrednisolone
Year: 2007 PMID: 18055980 DOI: 10.3324/haematol.11312
Source DB: PubMed Journal: Haematologica ISSN: 0390-6078 Impact factor: 9.941